Oscillations in serum ferritin associated with antiviral therapy in chronic hepatitis C;Oscilaciones de la ferritina sérica asociadas al tratamiento antiviral en la hepatitis crónica por virus C

Revista Espanola de Enfermedades Digestivas

Volumn 101, Issue 1, 2009, Pages 31-40

  Ladero, José M ^a,b   Lopez Alonso G ^a   Devesa, M J ^a   Cuenca, F ^a   Ortega, L ^a   Agreda, M ^a   Suarez A ^a   Ropero, P ^a   Diaz Rubio M ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

Hepatitis C; Pegylated interferon; Ribavirin; Serum ferritin

Indexed keywords

FERRITIN; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADULT; ARTICLE; DISEASE ASSOCIATION; DRUG EFFECT; FEMALE; FERRITIN BLOOD LEVEL; HEMOSIDEROSIS; HEPATITIS C; HUMAN; IRON OVERLOAD; MAJOR CLINICAL STUDY; MALE; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; BLOOD; MIDDLE AGED;

ANTIVIRAL AGENTS; FEMALE; FERRITINS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED;

EID: 66149192682     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: 10.4321/S1130-01082009000100004     Document Type: Article

References (27)

1. Metwally MA, Zein CO, Zein NN. Clinical significance of hepatic iron deposition and serum iron values in patients with chronic hepatitis C infection. Am J Gastroenterol 2004; 99: 286-291 (Pubitemid 38279871)
2. Guyader D, Thirouard AS, Erdtmann L, Rakba N, Jacquelinet S, Danielou H, et al. Liver iron is a surrogate marker of severe fibrosis in chronic hepatitis C. J Hepatol 2007; 46: 587-595 (Pubitemid 46400139)
3. Shedlofsky SI. Role of iron in the natural history and clinical course of hepatitis C disease. Hepatogastroenterology 1998; 45: 263-269 (Pubitemid 28167649)
4. Eisenbach C, Gehrke SG, Stremmel W. Iron, the HFE gene, and hepatitis C. Clin Liver Dis 2004; 8: 775-785 (Pubitemid 39311144)
5. Distante S, Bjoro K, Hellum KB, Myrvang B, Berg JP, Skaug K, et al. Raised serum ferritin predicts non-response to interferon and ribavirin treatment in patients with chronic hepatitis C infection. Liver 2002; 22: 269-275 (Pubitemid 34846366)
6. Ladero JM, Ropero P, Ortega L, Taxonera C, González FA, López-Alonso G et al. HFE gene mutations, hepatic iron content, and histological severity in hepatitis C virus-induced chronic hepatitis. Rev Esp Enferm Dig 2003; 95: 833-836 (Pubitemid 38100788)
7. Silva IS, Perez RM, Oliveira PV, Cantagalo MI, Dantas E, Sisti C, et al. Iron overload in patients with chronic hepatitis C virus infection: clinical and histological study. J Gastroenterol Hepatol 2005; 20: 243-248 (Pubitemid 40343276)
8. Valenti L, Pulixi EA, Arosio P, Cremonesi L, Biasiotto G, Dongiovanni P, et al. Relative contribution of iron genes, dysmetabolism and hepatitis C virus (HCV) in the pathogenesis of altered iron regulation in HCV virus hepatitis. Hematologica 2007; 92: 1037-1042 (Pubitemid 350144209)
9. García-Buey ML, González F. Iron overload and chronic hepatitis C: the role of HFE gene mutations. Rev Esp Enferm Dig 2003; 95: 824-828
10. Weiss G. Modification of iron regulation by inflammatory response. Best Pract Res Clin Haematol 2005; 18: 183-201. (Pubitemid 40298364)
11. Di Bisceglie AM, Axiotis CA, Hoofnagle JH, Bacon BR. Measurements of iron status in patients with chronic hepatitis. Gastroenterology 1992; 102: 2108-2113
12. Shan Y, Lambrecht RW, Bomkovsky HL. Association of hepatitis C virus infection with serum iron status: Analysis of data from the third National Health and Nutrition Examination Survey. Clin Infect Dis 2005; 40: 834-841 (Pubitemid 40365503)
13. Cazzola M. Role of ferritin and ferroportin genes in unexplained hyperferritinemia. Best Pract Res Clin Haematol 2005; 18: 251-263 (Pubitemid 40298368)
14. Janka GE. Hemophagocytic syndrome. Blood Rev 2007; 21: 245-253
15. Erhardt A, Maschner-Olberg A, Mellenthin C, Kappert G, Adams O, Donner A, et al. HFE mutations and chronic hepatitis C: H63D and C282Y heterozygosity are independent risk factors for liver fibrosis and cirrhosis. J Hepatol 2003; 38: 335-342 (Pubitemid 36286547)
16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981; 1: 431-435 (Pubitemid 12218164)
17. Zeuzem S, Fried MW, Reddy KR, Marcellin P, Diago M, Craxi A, et al. Improving the clinical relevance of pre-treatment viral load as a predictor of sustained virological response (SVR) in patients infected with hepatitis C genotype 1 treated with peginterferon alfa-2a (40 kDa) (PEGASYS) plus ribavirin (COPEGUS). Hepatology 2006; 44: 267A.
18. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006; 355: 2444-2451 (Pubitemid 44903748)
19. Chevaliez S, Pawlotsky J-M. Interferon-based therapy of hepatitis C. Adv Drug Deliv Rev 2007; 59: 1222-1241 (Pubitemid 350047513)
20. Torti FM, Torti SV. Regulation of ferritin genes and protein. Blood 2002; 99: 3505-3516 (Pubitemid 34534516)
21. Tilg H, Kaser A. Type I interferons and their therapeutic role in Th2-regulated inflammatory disorders. Expert Opin Biol Ther 2004; 4: 469-481 (Pubitemid 38480547)
22. Stam TC, Swaak AJ, Kruit WH, Eggermont AM. Regulation of ferritin: a specific role for interferon-alpha (IFN-alpha)? The acute phase response in patients treated with IFN-alpha-2b. Eur J Clin Invest 2002; 32(Supl. 1): 79-83. (Pubitemid 41704992)
23. Ferrara F, Guido M, Ventura P, Geetti A, Abbati G, Corradini E, et al. Antiviral treatment profoundly affects iron status in HCV patients: implications for management and treatment outcome. J Hepatol 2006; 46(Supl. 1): S222.
24. Lebray P, Zylberberg H, Hue S, Poulet B, Carnot F, Martin S, et al. Influence of HFE gene polymorphisms on the progression and treatment of chronic hepatitis C. J Viral Hepat 2004; 11: 175-182 (Pubitemid 38365769)
25. Bonkovsky HL, Naishadham D, Lambrecht RW, Chung RT, Hoefs JC, Nash SR, et al. Roles of iron and HFE mutations on severity and response to therapy during retreatment of advanced chronic hepatitis C. Gastroenterology 2006; 131: 1440-1451 (Pubitemid 44780862)
26. Gattoni A, Parlato A, Bangieri B, Bresciani M, Derna R, Baldassare R. Role of hemochromatosis genes in chronic hepatitis C. Clin Ter 2006; 157: 61-68 (Pubitemid 44898233)
27. Hofer H, Österreicher C, Jessner W, Penz M, Steindl-Munda P, Wrba F, et al. Hepatic iron concentration does not predict response to standard and pegylated-IFN/ribavirin therapy in patients with chronic hepatitis C. J Hepatol 2004; 40: 1018-1022 (Pubitemid 38670137)